Type II DM subjects: LBP 300mg/day vs Type II DM control
37/30
Double blind RCT
Serum glucose
Glucose AUC decreased in LBP group vs placebo (-7.86 % vs. 1.61 %)
RCT evidence for clinical efficacy of supplementary LBP treatment for vascular risk factor control in type II DM subjects However, potential impact limited by a small sample size
Insulinogenic index
Increased from -0.98 % to 0.04 % in LBP treated
Serum lipid
Significantly raised HDL in LBP compared to control
Overweight subjects: LB juice (30/60/120ml) vs control
8
Double blind, placebo controlled RCT
RMR + PPEE
LB group: 58.26±5.72ml/min (VO2) increase 1hr after intake, significantly higher than baseline
RCT evidence for clinical efficacy of supplementary LBP treatment in waist circumference reduction for overweight subjects Mechanism suggested to be through increase in basal metabolic rate However, it is important to note that change in VO2 is a crude measurement for basal metabolic rate
14/19
Waist circumference
LB group: 5.54±0.65cm reduction after 15 days treatment compared to baseline
Total papers = 2
Abbreviations. a-Lycium barbarum, b-randomised control trial (RCT), c- resting metabolic rate (RMR), postprandial energy expenditure (PPEE), d-area under curve (AUC), high-density lipoproteins (HDL), and breath oxygen volume (VO2).